Healthcare Services

Multiple Myeloma Market Outlook 2026–2030 Exploring New Business Opportunities

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Multiple Myeloma Market In 2026 And What Value Is Projected For 2030?

The multiple myeloma market has experienced robust expansion in recent years. It is projected to grow from $28.05 billion in 2025 to $30.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to an increased prevalence of hematologic cancers, the early adoption of chemotherapy agents, a rise in diagnostic imaging utilization, the expansion of hospital-based treatment facilities, and the development of first-generation immunomodulatory drugs.

The multiple myeloma market is projected to experience significant expansion over the coming years, with its size forecast to reach $41.39 billion in 2030, exhibiting an 8.2% compound annual growth rate (CAGR). This projected growth during the forecast period is driven by progress in targeted therapies, an increasing need for stem cell transplants, the expansion of precision medicine applications, a growing pipeline of clinical trials, and the wider adoption of monoclonal antibody therapies. Noteworthy trends for the forecast period include the escalating development of innovative immunotherapies, the increasing incorporation of monoclonal antibodies into treatment protocols, a rising preference for minimally invasive diagnostic techniques, the proliferation of stem cell transplantation procedures, and an intensified focus on combination therapies for enhanced patient outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12163&type=smp

What Key Drivers Are Influencing The Growth Of The Multiple Myeloma Market?

The growing occurrence of multiple myeloma is anticipated to drive the expansion of the multiple myeloma market in the future. This particular cancer originates in plasma cells, which are a type of white blood cell. Factors contributing to the rise in multiple myeloma cases include age, genetic predisposition, obesity, exposure to radiation, and various other health conditions. Treatments for multiple myeloma are designed to impede its progression and alleviate its associated symptoms. For instance, projections released in February 2025 by the American Cancer Society, a US-based voluntary health organization, indicate that in the United States, around 36,110 new multiple myeloma cases and approximately 12,030 associated deaths are anticipated in 2025, affecting both men and women. Consequently, the rising prevalence of multiple myeloma is fueling the expansion of the multiple myeloma market.

What Are The Key Segments Of The Multiple Myeloma Market?

The multiple myeloma market covered in this report is segmented –

1) By Treatment: Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments

2) By Diagnosis: Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests

3) By Disease Type: Active Multiple Myeloma, Smoldering Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Medications: Immunomodulatory Drugs (IMiDs), Proteasome Inhibitors, Monoclonal Antibodies, Corticosteroids, Chemotherapy Agents

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioisotope Therapy

3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT), Allogeneic Stem Cell Transplant

4) By Other Treatments: Supportive Care, Clinical Trials And Experimental Therapies

Which Trends Are Influencing The Multiple Myeloma Market?

Leading companies in the multiple myeloma market are concentrating on developing innovative therapies, such as CAR T-cell therapy, to achieve a competitive advantage. Chimeric Antigen Receptor T-cell therapy is an immunotherapy that involves genetically modifying a patient’s T cells to express a chimeric antigen receptor, allowing them to recognize and target specific cancer cells. For instance, in December 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, obtained approval for Abecma, making it the first CAR T-cell therapy approved for earlier application in patients with relapsed or refractory multiple myeloma (RRMM) who have undergone at least two prior therapies. Abecma is a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy. This approval was based on the interim analysis of the KarMMa-3 Phase 3 study, which demonstrated a significant improvement in median progression-free survival (mPFS) and a higher overall response rate (ORR) in the Abecma treatment group.

Who Are The Leading Companies Operating In The Multiple Myeloma Market?

Major companies operating in the multiple myeloma market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Karyopharm Therapeutics Inc., Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Xencor Inc., Oncopeptides AB, BeiGene Ltd., TG Therapeutics Inc.

Read the full multiple myeloma market report here:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Multiple Myeloma Market?

North America was the largest region in the multiple myeloma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Multiple Myeloma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12163&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Market 2026, By The Business Research Company

Disability Insurance Global Market Report

https://www.thebusinessresearchcompany.com/report/disability-insurance-global-market-report

Pet Healthcare Global Market Report

https://www.thebusinessresearchcompany.com/report/pet-healthcare-global-market-report

Pet Diabetes Care Global Market Report

https://www.thebusinessresearchcompany.com/report/pet-diabetes-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795